The Class I HDAC Inhibitor Valproic Acid Strongly Potentiates Gemcitabine Efficacy in Pancreatic Cancer by Immune System Activation

The Class I HDAC Inhibitor Valproic Acid Strongly Potentiates Gemcitabine Efficacy in Pancreatic Cancer by Immune System Activation

Background: Gemcitabine efficacy in pancreatic cancer is often impaired due to limited intracellular uptake and metabolic activation. Epi-drugs target gene expression patterns and represent a promising approach to reverse chemoresistance. In this study, we investigate the chemosensitizing effect of...

Full description

Bibliographic Details
Main Authors: Amber Blaauboer, Peter M. van Koetsveld, Dana A. M. Mustafa, Jasper Dumas, Fadime Dogan, Suzanne van Zwienen, Casper H. J. van Eijck, Leo J. Hofland
Format: Article
Language:English
Published: MDPI AG 2022-02-01
Series:Biomedicines
Subjects:
pancreatic cancer
gemcitabine resistance
valproic acid
immune activation
Online Access:https://www.mdpi.com/2227-9059/10/3/517

Internet

https://www.mdpi.com/2227-9059/10/3/517

Similar Items